세계의 진행성 운동실조증 및 근력 저하증 치료제 시장

Highlights:

The global progressive ataxia and weakness disorders market reached $32.0 billion in 2022, should reach $35.1 billion by 2023 and $57.2 billion by 2028 with a compound annual growth rate (CAGR) of 10.2% during the forecast period of 2023-2028.

Progressive weakness syndromes segment of the global progressive ataxia and weakness disorders market reached $29.9 billion in 2022, should reach $32.8 billion by 2023 and $52.8 billion by 2028 with a CAGR of 10.0% during the forecast period of 2023-2028.

Progressive ataxia segment of the global progressive ataxia and weakness disorders market reached $2.1 billion in 2022, should reach $2.4 billion by 2023 and $4.4 billion by 2028 with a CAGR of 13.3% during the forecast period of 2023-2028.

Report Scope:

The scope of this study encompasses the neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, the technologies involved, market projections and market shares. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes India, China, Japan, Canada and Australia. The report informs all market players, potential entrants, government agencies and other interested parties. As the report covers geographic regions in detail, companies interested in expanding geographic reach will also find this helpful.

This report also covers merger and acquisition (M&A) strategies and collaborations, as well as the strengths and weaknesses of each strategy type.

Report Includes:

• 34 data tables and 34 additional tables
• A comprehensive overview of the current and future global markets for the treatments of progressive ataxia and weakness disorders
• Analyses of the global market trends, with historical market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024 and 2026, and projections of compound annual growth rates (CAGRs) through 2028
• In-depth information (facts and figures) concerning the major factors influencing the progress of this market (benefits, and industry-specific challenges) with respect to specific growth trends, upcoming technologies, future prospects, and contributions to the overall market
• Estimation of the actual market size and revenue forecast for global progressive ataxia and weakness disorders treatments market in USD million values, and corresponding market share analysis based on product, technology, disease type, application, distribution channel, and region
• Discussion of the applications for neurodegenerative disorder treatment and therapy technologies, with emphasis on small-molecule and monoclonal antibodies technology
• Identification of critical medical and geographical challenges as well as economic and demographic factors affecting the market growth
• Review of key patent grants and recent patent applications on neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets, along with emerging technologies and new developments
• Coverage of recent merger and acquisition (M&A) activities, venture fundings, and other impactful growth strategies in the global market neurodegenerative (i.e., progressive ataxia and weakness) disorders
• Identification of the key players operating in the market, and analysis of their competitive landscape based on recent developments, segmental revenues, and operational integration
• Company profiles of major players within the industry, including Abbott Laboratories, Glenmark Life Sciences, Novartis AG, Pfizer Inc., Roche Holding Ltd., and Sanofi

Table of Contents

Chapter 1 Introduction

• Overview
• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• What's New in This Update?
• Methodology
• Information Sources
• Geographic Breakdown

Chapter 2 Summary and Highlights

• Market Overview

Chapter 3 Market Overview

• Introduction
• Definitions
• Neurons
• Central Nervous System
• Brain
• Spinal Cord
• Neurotransmitters
• Classification
• Progressive Ataxia and Weakness Disorders
• Friedreich's Ataxia
• Gertsmann-Straussler-Scheinker Disease
• Machado-Joseph Disease/SCA3
• Amyotrophic Lateral Sclerosis
• Hereditary Spastic Paraplegia
• Hereditary Neuropathies
• Multiple Sclerosis
• Diagnostic Tests for Progressive Ataxia and Weakness Disorders
• Diagnostic Tests for Multiple Sclerosis
• Diagnostic Tests for Amyotrophic Lateral Sclerosis
• Diagnostic Tests for Friedreich's Ataxia
• Diagnostic Tests for Machado-Joseph Disease
• Diagnostic Tests for Hereditary Spastic Paraplegia
• Diagnostic Tests for Hereditary Neuropathies

Chapter 4 Market Dynamics

• Introduction
• Market Drivers
• Progressive Ataxia and Weakness: Increasing Prevalence and Awareness
• Technological Advancements and Product Launch
• Increasing Expenditures for Health Care
• Rise in Alcohol and Drug Use
• Market Barriers
• Barriers to R&D for Progressive Ataxia
• Diagnostic Challenges
• Opportunities
• Advancements in Research and Technology
• Impact of COVID-19, Global Market for Treatment for Syndromes of Progressive Ataxia and Weakness Disorders

Chapter 5 Market Breakdown by Type and Technology

• Introduction
• Market by Type
• Market Overview
• Market Revenue
• Market by Technology
• Market Overview
• Market Revenue
• Small Molecule
• Market Overview
• Market Revenue
• Monoclonal Antibody
• Market Overview
• Market Revenue
• Others
• Biomarkers
• Gene Therapy
• Stem Cell
• Market Overview
• Market Revenue

Chapter 6 Market Breakdown by Disease

• Overview
• Market Revenue
• Market by Progressive Ataxia Diseases Type
• Friedreich's Ataxia
• Market Revenue
• Machado-Joseph disease (MJD)/SCA3
• Market Revenue
• Gertsmann-Straussler-Scheinker Disease
• Market Revenue
• Market by Disease Type
• Amyotrophic Lateral Sclerosis
• Progressive Bulbar Palsy
• Hereditary Spastic Paraplegia
• Hereditary Neuropathies (HNs)
• Multiple Sclerosis (MS)

Chapter 7 Market Breakdown by Region

• Introduction
• North America
• The U.S.
• Canada
• Europe
• The UK
• Germany
• France
• Spain
• Italy
• Russia
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia
• Rest of Asia-Pacific
• Rest of the World
• Market Size and Forecast

Chapter 8 Market Breakdown by Distribution Channel

• Introduction
• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy

Chapter 9 Emerging Technologies and Developments

• Introduction
• Emerging Technology
• Stem Cell Therapy
• Gene Therapy
• Biomarkers
• Nasal Spray for MS
• Disease-modifying Therapies
• RNA-based Therapies
• Conclusion

Chapter 10 ESG Development

• Introduction
• ESG Investments by Key Players
• Consumer Attitudes Towards ESG
• Conclusion

Chapter 11 Patent Analysis

• Patent Analysis by Year

Chapter 12 M&A and Venture Funding Outlook and Competitive Landscape

• Introduction
• Mergers, Acquisitions and Collaborations
• Strategic Initiatives
• Market Shares of Manufacturers of Progressive Ataxia and Weakness Disorders Drugs

Chapter 13 Company Profiles

• ABBOTT LABORATORIES
• ACORDA THERAPEUTICS INC.
• AMERICAN REGENT INC.
• APOTEX INC.
• APOTHECA INC.
• ASTELLAS PHARMA INC.
• ASTRAZENECA GMBH
• BAXTER INTERNATIONAL INC.
• BRISTOL-MYERS SQUIBB
• EISAI CO. LTD.
• ELI LILLY AND COMPANY
• GILEAD SCIENCES INC.
• GLAXOSMITHKLINE PLC
• GLENMARK LIFE SCIENCES
• JOHNSON & JOHNSON
• MERCK KGAA
• NOVARTIS AG
• PFIZER INC.
• ROCHE HOLDING LTD.
• SANOFI
• TAKEDA PHARMACEUTICAL CO. LTD.
• TEVA PHARMACEUTICAL INDUSTRIES LTD.

Chapter 14 Appendix: Abbreviations